VFY — Vitrafy Life Sciences Income Statement
0.000.00%
Last trade - 00:00- AU$92.58m
- AU$115.92m
- AU$0.04m
Annual income statement for Vitrafy Life Sciences, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0 | 0.032 | 0.037 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 3.26 | 4.62 | 7.18 | 8.66 |
| Operating Profit | -3.26 | -4.62 | -7.15 | -8.62 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -3.06 | -7.66 | -7.81 | -10.4 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -3.06 | -7.66 | -7.81 | -10.4 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -3.06 | -7.66 | -7.81 | -10.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -3.06 | -7.66 | -7.81 | -10.4 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.048 | -0.12 | -0.122 | -0.163 |
| Dividends per Share |